EMOR - Emerald Organic Products Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
1.8500
+0.2699 (+17.08%)
At close: 2:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.5801
Open1.8000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.8000 - 1.9000
52 Week Range0.3100 - 4.8900
Volume1,975
Avg. Volume753
Market Cap144.284M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Nationwide On-Site Coronavirus Testing Program

    REHOVOT, ISRAEL, July 06, 2020 -- via NEWMEDIAWIRE ‒ Meridian HSN has partnered with Moto-Para and Todos Medical (OTCQB: TOMDF) to provide a complete turnkey solution for.

  • GlobeNewswire

    Todos Medical Enters Into Distribution Partnership With Meridian Health Services Network for COVID-19 Testing Solutions

    REHOVOT, Israel, NEW YORK, NY  and BOULDER, CO, June 29, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into a partnership with Meridian Health Services Network (“Meridian,” www.meridianhsn.com) to deploy COVID-19 testing programs throughout the United States. As part of the agreement, Todos will be working closely with Meridian to help supplement COVID-19 testing products and services for its network of brick & mortar and mobile laboratories nationwide.

  • GlobeNewswire

    Emerald Organic Products Launches Emerald Shield™ Division Alongside Nationwide Reopening and ‘Second Wave’ of Coronavirus

    Emerald Organic Products, Inc. (OTC: EMOR) (the “Company”, "Emerald Organic", or "Emerald Organic Products"), a diversified health sciences company, is pleased to announce the launch of Emerald Shield™, an all-encompassing solution developed to facilitate necessary initiatives in a safety-conscious post-COVID-19 world. With a mission to support communities, companies, and municipalities across the United States, Emerald Shield’s key focus areas are its technologically-driven public safety solutions, and transformative health and wellness platforms. As communities reopen, businesses and government agencies are actively seeking effective ways to keep the state safe by working with companies like Emerald Shield who specialize in sanitizing solutions.

  • GlobeNewswire

    Todos Medical Enters Into Exclusive Distribution Agreement With NLC Pharma for Saliva-based Onsite COVID-19 Diagnostic Test

    REHOVOT, Israel, and NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into an exclusive worldwide distribution agreement with Israel-based NLC Pharma to commercially develop its patented virus-focused 3C Protease diagnostic platform for the diagnosis of COVID-19. “3C Protease quantitation presents a unique approach to viral replication monitoring, and could prove to be a significant tool in the fight against COVID-19,” said Jorge Leon, PhD, Senior Medical Advisor to Todos.

  • GlobeNewswire

    Todos Medical Enters Into Direct Exclusive Distribution Agreement With Gnomegen and Announces US FDA Emergency Use Authorization for its COVID-19 qPCR Test Kits

    ·       Exclusive Distribution agreement covers North America, Latin America, SE Asia, Europe ·       Validation of Gnomegen qPCR kits now complete at CLIA/CAP-certified.

  • GlobeNewswire

    Emerald Organic Products Restructures Joint Venture Agreement with Todos Medical By Entering Joint Collaboration Agreement

    HOLBROOK, NY, REHOVOT, ISRAEL, SINGAPORE AND NEW YORK, NY, May 08, 2020 -- Emerald Organic Products, Inc. (OTC: EMOR) ("Emerald") a diversified health sciences and technology.

  • GlobeNewswire

    Emerald Organic Products Completes Successful Hand Sanitizer Product Pilot

    Emerald Organic Products, Inc. (OTC: EMOR) (the “Company”, "Emerald", "Emerald Organic", or "Emerald Organic Products") a diversified health sciences and technology company, is pleased to announce that the Company has successfully completed its product pilot for NxGen Hand Sanitizer (the “Product Pilot”), selling out thousands of bottles within one week of launch. “The great reception we received from the market for our NxGen hand sanitizer Product Pilot tells us that we are in the right sector, with the right product,” commented Ian Parker, Chief Executive Officer of Emerald Organic Products.

  • GlobeNewswire

    Emerald Organic Products Congratulates Portfolio Company, Bonsa Health, on Recent Prescription Delivery Partnerships

    Emerald Organic Products, Inc. (OTC: EMOR) (the “Company”, "Emerald", "Emerald Organic", or "Emerald Organic Products") a diversified health sciences company, is pleased to announce that subsequent to the Company’s press release on March 27, 2020 regarding Emerald’s acquisition of a 51% controlling stake in Bonsa Health (the “Acquisition”), Bonsa Health has announced four new prescription delivery partnerships (the “Partnerships”), highlighting the platform’s rapid growth and expansion as the demand for same-day delivery of prescriptions and medications has increased dramatically due to self-quarantining and self-isolation amid the COVID-19 pandemic.

  • GlobeNewswire

    Todos Medical Announces US FDA Emergency Use Authorization Allowed for Gnomegen COVID-19 PCR Test Kits

    Gibraltar Brothers & Associates, LLC has entered into agreements with Gnomegen, LLC to supply Todos with its proprietary Real Time digital PCR Test Kits for COVID-19.

  • GlobeNewswire

    Todos Medical Appoints Dr. Lauren Chung to its Board of Directors

    REHOVOT, Israel, SINGAPORE and NEW YORK, NY, April 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --Todos Medical Ltd. (TOMDF), a commercial in vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders as well as point-of-care and lab-based tests for COVID-19, announces the appointment of Lauren Chung, Ph.D. to its Board of Directors. This appointment increases the size of the Todos Medical Board to 7 Directors, including 2 independent Directors. Dr. Chung has been named lead independent Director, and will serve as Chair of both the Compensation Committee and the Nomination and Governance Committee.

  • GlobeNewswire

    Todos Medical Achieves Medical Importer Status with US FDA

    REHOVOT, Israel, SINGAPORE and NEW YORK, NY, April 15, 2020 -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), a commercial in vitro diagnostics company focused on the.

  • GlobeNewswire

    Todos Medical Provides Corporate Update

    REHOVOT, ISRAEL, SINGAPORE and NEW YORK, NY, April 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (TOMDF), a pre-commercial stage in vitrodiagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, announces that its President and Chief Executive Officer Gerald E. Commissiong has provided the following corporate update on the Company’s ongoing initiatives, including progress with its novel coronavirus (COVID-19) joint venture Corona Diagnostics, LLC,  the ongoing breast cancer commercialization trial with its proprietary blood spectroscopy platform, and the pending acquisition of its Alzheimer’s disease joint venture Breakthrough Diagnostics, Inc. Through our entities and teams in the U.S., Israel and Singapore, we are working through the various regulatory and international import/export requirements in order to initiate sales in the United States and abroad.

  • GlobeNewswire

    Emerald Organic Products Inc. Acquires Leading Telehealth Company Carie Health Inc.

    Emerald Organic Products Inc. (OTC: EMOR) ("Emerald" or the "Company") a high growth diversified health science and technology company, today has entered into a definitive agreement to acquire Carie Health Inc. (“Carie”), a leading telehealth and virtual care technology and service solutions company. “Founded in 2016, Carie has quickly matured into a fully-proprietary end-to-end telehealth solution capable of scaling up to lead America’s transition to a more consumer friendly, virtual healthcare model,” said Matt Wanderer, Founder and CEO of Carie Health.

  • GlobeNewswire

    Todos Medical Expands on Coronavirus (COVID-19) Distribution Agreement with Shanghai Liangrun Subsidiary Gibraltar

    Todos expands rights to include Asian countries and to include PCR test kits Corona Diagnostics JV with Emerald Organic responsible for commercialization Dr. Joseph Wee,.

  • GlobeNewswire

    Emerald Organic Products Acquires Digital Pharmacy Bonsa Health

    In the age of technological advances and need for modern convenience, Bonsa offers an all encompassing tech-driven digital solution that creates an effective, secured communication line between providers, patients, and pharmacists to expedite prescription fulfillment and same day delivery. Bonsa is expecting to enhance its current same-day delivery to offer 3-hour national delivery by January 2021.

  • Coronavirus (COVID-19)-Focused Joint Venture Formed Between Emerald Organic and Todos Medical to Supply U.S. Market With Rapid Point-of-Care Screening and Confirmatory Testing Kits
    PR Newswire

    Coronavirus (COVID-19)-Focused Joint Venture Formed Between Emerald Organic and Todos Medical to Supply U.S. Market With Rapid Point-of-Care Screening and Confirmatory Testing Kits

    Emerald Organic Products, Inc. (OTC: EMOR) and Todos Medical Ltd. (OTCQB: TOMDF) today announced the creation of Corona Diagnostics, LLC, a joint venture partnership formed to address the much-needed demand for COVID-19 screening and diagnostic testing in the United States. The joint venture will be owned 51% by Emerald and 49% by Todos.

  • GlobeNewswire

    Alliance Funding Group Extends a $20 Million Sales Finance Line to Emerald Organic for Commercialization of its Proprietary, HIPAA Compliant Facial Recognition-enabled Vending Machines

    Alliance has been in the equipment leasing sector since 1998 and financed well over $2B+ in assets to 25,000+ businesses throughout the United States. With 100+ employees and offices in Orange County, Los Angeles and Portsmouth, NH, Alliance has the scale to address the needs of OEM’s and distributors of all sizes while also providing the flexibility of an entrepreneurial equipment lessor.

  • GlobeNewswire

    Emerald Organic Reaches Definitive Agreement for a $5 Million Injection of Private Equity Capital

    Bedrock is a private equity firm focused on providing growth capital to select emerging growth companies. Under the terms of the agreement, Bedrock will be entitled to covert its $5M in Series C Preferred Stock investment into common shares of the Company at a fixed price of $1.60. “After working with Emerald Organic’s management team over the last several months, we believe we have finally found the right leadership group to make our first investment in the hemp space,” said J. Roth, Manager of Bedrock.

  • GlobeNewswire

    Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products

    Emerald gains exclusive worldwide development rights to ESS, MANF and PhenoGuard Amarantus receives Emerald preferred stock valued at a minimum of $66.6 million New.

  • GlobeNewswire

    Emerald Organic Products to Acquire Vending Machine Company

    Holbrook, New York, Nov. 11, 2019 -- Emerald Organic Products, Inc. (OTC:EMOR) (“Emerald” or the “Company”), a diversified cannabidiol (“CBD”) products company, is pleased to.

  • PR Newswire

    Emerald Organic Products to License Therapeutics Portfolio from Amarantus Bioscience Holdings

    Portfolio includes treatments for Alzheimer's disease, ADHD, Parkinson's disease, vision loss and severe burns Amarantus to receive Emerald Organics Preferred Stock for the exclusive worldwide license ...

  • GlobeNewswire

    Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products

    NEW YORK, NY, Oct. 24, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced it has entered into a binding term sheet to license its therapeutic assets to Emerald Organic Growth, Inc. (EMOR) (“Emerald” or EMOR), a fully-integrated, CBD-based health sciences company launching branded products via its nationwide distribution channels. Amarantus will receive Emerald Preferred Stock to be valued at a minimum of $100M in 2022, and up to double digit royalties (in addition to passthrough royalties and milestones) in exchange for worldwide, exclusive development and commercial rights to eltoprazine, engineered skin substitute (ESS), mesencephalic astrocyte-derived neurotrophic factor (MANF) and PhenoGuard.

  • GlobeNewswire

    Emerald Organic Products Hires Ex-Quest Nutrition Executive as Head of Sales

    Holbrook, New York, Sept. 30, 2019 -- Emerald Organic Products, Inc. (OTC:EMOR) (“Emerald” or the “Company”) is pleased to announce the addition of former Quest Nutrition, LLC.

  • GlobeNewswire

    Pura Vida Vitamins' Watermelon CBD Gummy Rings Win Buyers Choice Award

    Holbrook, NY, Sept. 17, 2019 -- Emerald Organic Products, Inc. (OTC:EMOR) (“Emerald” or the “Company”) is pleased to announce that its Watermelon Pura CBD Gummy Rings, produced.

  • GlobeNewswire

    Emerald Organic Products, Inc. Announces Exclusive Licensing Agreement With PetVivo Holdings Inc.

    Emerald Organic Products, Inc. (OTC:EMOR) (“Emerald” or the “Company”) is pleased to announce that it has formally entered into an exclusive licensing agreement for the use of OraPatch™, a patented oral delivery method for various substances including caffeine and cannabidiol (“CBD”) from PetVivo Holdings, Inc. (OTC:PETV) (“PetVivo”). Furthermore, the OraPatch product only uses materials deemed to be Generally Recognized as Safe (“GRAS”) by the United States Food and Drug Administration (the “FDA”). John Lai, President of PetVivo said, “We were waiting for the right consumer branding team to license this extraordinary, cutting edge technology to.